Meds & supplements › Nusinersen
Medicine · Survival Motor Neuron-2-directed RNA Interaction
Nusinersen
SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
Drug facts
- Used for
- SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Side effects, and when to stop
The following serious adverse reactions are described in detail in other sections of the labeling:
- Thrombocytopenia and Coagulation Abnormalities
- Renal Toxicity
Who should not take it
None.
Storing it
Store in a refrigerator between 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze.
SPINRAZA should be protected from light and kept in the original carton until time of use.
If no refrigeration is available, SPINRAZA may be stored in its original carton, protected from light at or below 30 o C (86 o F) for up to 14 days.
Prior to administration, unopened vials of SPINRAZA can be removed from and returned to the refrigerator, if necessary. If removed from the original carton, the total combined time out of refrigeration should not exceed 30 hours at a temperature that does not exceed 25 o C (77 o F).
Cite this page
- NLM
sofidex [Internet]. Daloreum; c2026. Nusinersen; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/nusinersen
- APA 7th
sofidex. (2026, August 3). Nusinersen. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/nusinersen
- AMA 11th
Nusinersen. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/nusinersen
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.